MRNA cancer therapy takes on blood tumors

NCT ID NCT07349849

Recruiting now Disease control Sponsor: Xinqiao Hospital of Chongqing Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental mRNA-based drug that turns the body's own cells into cancer fighters. The drug targets CD19, a protein found on certain blood cancer cells. Researchers will enroll 47 adults with B-cell lymphoma or leukemia who have run out of standard options. The main goals are to find a safe dose and check whether the drug can control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mRNA-based CAR-T drug delivered via lipid nanoparticles (LNP)
What this could lead to: If it works, this could lead to a simpler, off-the-shelf treatment for certain blood cancers that avoids the long wait and high cost of making personalized cell therapies.
What could go wrong: This is a very early, small study (47 people) focused on safety and dosing. The treatment may not shrink tumors, and side effects like cytokine release syndrome or organ damage are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm lymphoid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL MALIGNANCIES

Contacts and locations

Locations

Department of Hematology, Xinqiao Hospital
RECRUITING

Chongqing, Chongqing Municipality, 400037, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.